Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.32 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ECE1 | P42892 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8743224 | 0.86 | TSHR (0.39) | TSHRALDH1A1MAPK1TDP1LMNA | |
| SCHEMBL8743191 | 0.85 | SMN1; SMN2 (0.42) | TSHRALDH1A1MAPK1ZDHHC20ZDHHC2 | |
| SCHEMBL16371856 | 0.83 | PRMT1 (0.45) | TSHRALDH1A1MAPK1ZDHHC20ZDHHC2 | |
| SCHEMBL22675564 | 0.81 | TSHR (0.54) | TSHRALDH1A1MAPK1TDP1ZDHHC20 | |
| SCHEMBL9065524 | 0.77 | ALDH1A1 (0.37) | TSHRALDH1A1MAPK1TDP1LMNA | |
| SCHEMBL10018099 | 0.76 | EPHX1 (0.44) | TSHRALDH1A1MAPK1TDP1LMNA | |
| SCHEMBL4345550 | 0.75 | — | — | |
| SCHEMBL6363746 | 0.74 | PRSS1 (0.62) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6864093 | 0.74 | ALDH1A1 (0.38) | TSHRALDH1A1MAPK1TDP1ZDHHC20 | |
| SCHEMBL14395831 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975120-B2 | Site-specific chemoenzymatic protein modifications | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| EP-3613755-A1 | LYSINE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS USING MICROBIAL TRANSGLUTAMINASE | Novartis AG (CH) | 2020-02-26 | — | — | EP | disclosed |
| US-20190300570-A1 | SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20160237116-A1 | SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS | NOVARTIS AG | 2016-08-18 | — | — | US | disclosed |
| US-9359400-B2 | Site-specific chemoenzymatic protein modifications | NOVARTIS AG (CH) | 2016-06-07 | — | — | US | disclosed |
| EP-3019515-A2 | LYSINE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS USING MICROBIAL TRANSGLUTAMINASE | Usera, Aimee (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015006728-A2 | SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS | USERA AIMEE (US) | 2015-01-15 | — | — | WO | disclosed |
| EP-0751119-A1 | A process for preparing acryloyl carbamates or ureas | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1997-01-02 | — | — | EP | disclosed |
| US-4885355-A | Water-insoluble polymers from cyclic sulfonium compounds | THE DOW CHEMICAL COMPANY (US) | 1989-12-05 | — | — | US | disclosed |
| US-4797456-A | Aqueous-dispersible cyclic sulfonium compounds that cure to form water-insoluble polymers | THE DOW CHEMICAL COMPANY (US) | 1989-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300570-A1 | SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS | PTMS, TGM3, TGM1 | TSHR 3301/4885ALDH1A1 3164/4885MAPK1 4318/4885 |
| US-20160237116-A1 | SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS | PTMS, TGM3, TGM1 | TSHR 3301/4885ALDH1A1 3164/4885MAPK1 4318/4885 |
| US-10975120-B2 | Site-specific chemoenzymatic protein modifications | PTMS, TGM3, TGM1 | TSHR 3301/4885ALDH1A1 3164/4885MAPK1 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.